Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, James D. Lewis et al.|The Lancet|2022Cited by 295
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyVince Biemans, Frank Hoentjen, Andrea E. van der Meulen‐de Jong et al.|Journal of Crohn s and Colitis|2019Cited by 183
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, C. Janneke van der Woude, Gerard Dijkstra et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129
Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel DiseaseFrank Hoentjen, Adriaan A. van Bodegraven, Margien L. Seinen et al.|Inflammatory Bowel Diseases|2012Cited by 102
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryVince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 87